Genome analysis of patients with disorders of sex development, and gain-and loss-of-function studies in mice indicate that gonadal development is regulated by opposing signals. In females, the Wnt/␤-catenin canonical pathway blocks testicular differentiation by repressing the expression of the Sertoli cell-specific gene Sox9 by an unknown mechanism. Using cell and embryonic gonad culture models, we show that activation of the Wnt/␤-catenin pathway inhibits the expression of Sox9 and Amh, whereas mRNA and protein levels of Sry and steroidogenic factor 1 (Sf1), two key transcriptional regulators of Sox9, are not altered. Ectopic activation of Wnt/␤-catenin signaling in male gonads led to a loss of Sf1 binding to the Tesco enhancer and absent Sox9 expression that we also observed in wild-type ovaries. Moreover, ectopic Wnt/␤-catenin signaling induced the expression of the female somatic cell markers, Bmp2 and Rspo1, as a likely consequence of Sox9 loss. Wnt/␤-catenin signaling in XY gonads did not, however, affect gene expression of the steroidogenic Leydig cell Sf1 target gene, Cyp11a1, or Sf1 binding to the Cyp11a1 promoter. Our data support a model in ovary development whereby activation of ␤-catenin prevents Sf1 binding to the Sox9 enhancer, thereby inhibiting Sox9 expression and Sertoli cell differentiation. (Endocrinology 153: 901-912, 2012) S teroidogenic factor 1 (Sf1; Ad4BP/NR5A1) is an orphan nuclear hormone receptor member of the superfamily of nuclear hormone receptors (1, 2). Sf1 plays a central role in the development and function of steroidogenic tissues (3-5). Among those, Sf1 is essential for the development of the adrenal and gonads as targeted disruption of Sf1 in mice lead to adrenal and gonadal agenesis (6). Sf1 binds specific DNA sequences with high affinity and regulates the transcription of a number of steroidogenic P450 genes and is also involved in the transcriptional regulation of nonsteroidogenic target genes (reviewed in Ref. 7). In the developing gonad, Sf1 is specifically expressed in nonsteroidogenic Sertoli cells and steroidogenic Leydig cells, which suggests that it plays different roles in each cell type. In Sertoli cells, Sf1 regulates the transcription of Sox9 [sex determining region Y-box 9], which is essential for the proper development of male phenotype (8). Sf1 cooperation with sex determining region Y (Sry) in regulating Sox9 transcription is the key step to initiate the differentiation of Sertoli cells during male sex determination. Sox9 is a direct target gene of Sry action (8, 9) via a testis-specific enhancer of Sox9 (Tesco) in mice that is activated by a synergistic action of Sry and Sf1 (10). Maintenance of Sox9 expression throughout testicular differentiation is achieved by the action of the Fgf9 (fibroblast growth factor 9)-FgfR2 (fibroblast growth factor recep- Abbreviations: ABC, ␣-Active ␤-catenin; AMH, anti-Mü llerian hormone; BIO, 6-bromoindirubin-3Ј-oxime; Bmp2, bone morphogenic protein 2; ChIP, chromatin immunoprecipitation; Cyp11a1, cytochrome P450, family 11, subfamily A, polypeptide 1; dpc, days post coitum; GSK3, glycogen synthase kinase-3␤; HEK293, human embryonic kidney 293; LiCl, lithium chloride; Rspo1, R-spondin 1; Sf1, steroidogenic factor 1; Sox9, sex determining region Y-box 9; SRY, sex determining region Y; TCF, T cell factor; Wnt4, Winglessrelated mouse mammary tumor virus integration site 4; Wt1, Wilms tumor 1. 
S
teroidogenic factor 1 (Sf1; Ad4BP/NR5A1) is an orphan nuclear hormone receptor member of the superfamily of nuclear hormone receptors (1, 2) . Sf1 plays a central role in the development and function of steroidogenic tissues (3) (4) (5) . Among those, Sf1 is essential for the development of the adrenal and gonads as targeted disruption of Sf1 in mice lead to adrenal and gonadal agenesis (6) . Sf1 binds specific DNA sequences with high affinity and regulates the transcription of a number of steroidogenic P450 genes and is also involved in the transcriptional regulation of nonsteroidogenic target genes (reviewed in Ref. 7) . In the developing gonad, Sf1 is specifically expressed in nonsteroidogenic Sertoli cells and steroidogenic Leydig cells, which suggests that it plays different roles in each cell type. In Sertoli cells, Sf1 regulates the transcription of Sox9 [sex determining region Y-box 9], which is essential for the proper development of male phenotype (8) . Sf1 cooperation with sex determining region Y (Sry) in regulating Sox9 transcription is the key step to initiate the differentiation of Sertoli cells during male sex determination. Sox9 is a direct target gene of Sry action (8, 9 ) via a testis-specific enhancer of Sox9 (Tesco) in mice that is activated by a synergistic action of Sry and Sf1 (10) . Maintenance of Sox9 expression throughout testicular differentiation is achieved by the action of the Fgf9 (fibroblast growth factor 9)-FgfR2 (fibroblast growth factor recep-tor 2) and Ptgds-(prostaglandin D2 synthase)-Pgd2 (prostaglandin D2)-positive feedback loops (11, 12) as well as by the synergistic action of Sf1/Sox9 on the Tesco enhancer (10) . Sox9 and Sf1 also activate the transcription of the gene encoding anti-Mü llerian hormone (AMH), a hormone necessary to induce the regression of Mü llerian ducts that otherwise become the upper part of the vagina, the uterus, and the oviducts (13, 14) . In Leydig cells, Sf1 cooperates with ␤-catenin to activate the transcription of 3␤-hydroxysteroid dehydrogenase (3␤-HSD), CYP19 (cytochrome P450, family 19/aromatase) and steroidogenic acute regulatory protein (StAR) (15, 16) .
The Wnt/␤-catenin canonical pathway is involved in both promoting ovarian differentiation and blocking male testicular differentiation (17) . Ectopic activation of the Wnt pathway through stabilization of ␤-catenin leads to a male-to-female sex reversal phenotype in XY mice characterized by the loss of Sox9 and Amh expression (17) . However, the mechanism by which Sox9 expression is inhibited by ␤-catenin remains elusive. Given the importance of Sf1 in regulating the expression of Sox9 and Amh in Sertoli cells and steroidogenic target genes in Leydig cells, it is puzzling that Wnt signaling may repress Sertoli cell targets yet activate steroidogenic target genes in Leydig cells. Here we investigated the molecular mechanism of Wnt/␤-catenin pathway inhibition of testis development using an ex vivo model of testicular development. We report that ␤-catenin inhibits Sf1 function by inhibiting DNA binding of SF1 to Tesco, which in turn prevents Sox9 transcription from this testis-specific enhancer, leading to male-to-female sex reversal of the Sertoli cells. In contrast, activation of the Wnt signaling pathway did not inhibit Sf1 action on the Leydig cell steroidogenic target gene cytochrome P450, family 11, subfamily A, polypeptide 1 (Cyp11a1).
Materials and Methods

DNA constructs
Sry, Sox9, HA-tagged Sf1, and S37A ␤-catenin expression plasmids were previously described (18 -20) . The CYP11A1 promoter reporter plasmid was a kind gift from Dr. William E. Rainey (21) . The Tesco enhancer reporter was cloned by PCR into the E1b-luciferase reporter (22) .
Cell culture and transfections
NT2/D1 cells were grown in DMEM/F12 medium supplemented with 10% fetal bovine serum and L-glutamine in an atmosphere of 5% CO 2 . Human embryonic kidney 293 (HEK293) T cells were grown in DMEM medium supplemented with 10% fetal bovine serum and L-glutamine in an atmosphere of 5% CO 2 .Transient transfections were conducted using Fugene6 (Roche, Basel, Switzerland) in accordance with the manufacturer's instructions. Cells were seeded at a density of 0.5 ϫ 10 5 cells/well in 12-well plates 24 h before transfection. Thirty-six hours after transfection, the culture media were replaced with medium containing 20 mM LiCl, 5 M 6-bromoindirubin-3Ј-oxime (BIO), or vehicle (dimethylsulfoxide). After a 12-h treatment, the cell lysate was collected and luciferase reporter activity was measured according to the manufacturer's instructions (Promega, Madison, WI). Reporter activity was normalized to ␤-galactosidase as an internal control (Promega).
Quantitative real-time RT-PCR
NT2/D1 cells (ATCC CRL-1973, American Type Culture Collection, Manassas, VA) were treated with 20 mM LiCl. Total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA). RNA was treated with deoxyribonuclease I (Ambion, Austin, TX), and RNA quality was checked by 1.5% agarose gel electrophoresis and RNA quantitated by spectrophotometry at 260 nm. Then 0.5 g of total RNA was reverse transcribed in a 20-l reaction using Superscript II (Promega) according to the manufacturer's guidelines. One microliter of the cDNA product was used for PCR amplification using the SYBR green LightCycler fast start kit (Roche). PCR products were quantified using the LightCycler carousel-based system (Roche). Primer sequences for all the genes tested have been described (23, 24) . Specifically, ␤2-microglubulin was used as a housekeeping control gene as previously shown in NT2/D1 cells (23) and Rsp29 in mouse gonads (24) .
Antibodies
Goat polyclonal antibody against Amh (C-20, sc-6886) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse monoclonal antibody against Sry was purchased from Abcam (Cambridge, UK). Rabbit polyclonal antibody against Sf1 (06 -431) was purchased from Millipore (Billerica, MA). Mouse monoclonal antibody against nonphosphorylated ␤-catenin [␣-active ␤-catenin (ABC), clone 8E7] was purchased from Millipore (Billerica, MA). Rabbit polyclonal antibody against Sox9 has been described (11) . Alexa dye-linked and horseradish peroxidase-linked secondary antibodies were purchased from Molecular Probes (Eugene, OR).
Cryosection and immunofluorescence
Cultured gonads were fixed in 4% paraformaldehyde/PBS for 3 h at 4 C, washed twice in PBS, and incubated for 1 h in 15% sucrose/PBS and then overnight in 30% sucrose/PBS at 4 C. Samples were embedded in optimum cutting temperature medium (Tissue-Tek, Torrance, CA) and frozen at Ϫ70 C, and serial 5-m sections were cut with a cryostat (Leica, Heidelberg, Germany). Indirect immunofluorescence staining was performed as previously described (11) .
Western blot
NT2/D1 cells were seeded on to six-well plates at 0.3 ϫ 10 6 cells/well and cotransfected with the indicated plasmids by using the Fugene 6 reagent (Roche). Thirty-six hours after transfection, proteins were solubilized, and protein concentration was determined by Bradford assay (Bio-Rad protein assay kit; Bio-Rad Laboratories, Hemel Hempstead, UK). Cell lysates were incubated for 5 min at 95 C and resolved by SDS-PAGE. Proteins were transferred to a polyvinyl difluoride membrane (Immun-Blot polyvinyl difluoride 000membrane; Bio-Rad), incubated with primary antibodies, washed, and incubated with fluorescent conjugated secondary antibody. Membranes were scanned on the Odyssey Infrared Imaging System (LiCor, Lincoln, NE).
Mice
The Tesco-LacZ mice were a generous gift from Drs. Ryohei Sekido and Robin Lovell-Badge and were used to generate embryos for ex vivo gonad culture. All procedures involving mice were approved by the Animal Ethics Committee of Southern Health (Clayton, Australia).
Mouse embryonic gonad culture
Urogenital ridges were harvested at 11.5 d post coitum (dpc; 15-20 tail somites) and cultured at 37 C with 5% CO 2 in air in a 20-l drop of DMEM (Life Technologies, Inc., Carlsbad, CA), supplemented with 10% fetal calf serum (Life Technologies). Each gonad was suspended in a hanging drop from the lid of a 12-well plate. Gonads were then treated with 20 mM LiCl or 5 M BIO for 12 h. Medium was changed after 12 h, and gonads were grown for 3 d before harvesting with the exception of Sry immunohistochemistry (see Fig. 4 ) in which some gonads were treated for 12 h and immediately processed. As a negative control, the contralateral gonads were also cultured but left untreated. Sex genotyping was performed on yolk sac DNA as described previously (11) .
Chromatin immunoprecipitation (ChIP)
ChIP was performed on explanted gonads using at least 50 pairs of gonads according to the Chip protocol (25) . Sf1 binding to the Tesco enhancer was monitored using primer Set5 forward, 5Ј-GCAGATACCAACTACAGG-3Јand primer Set5 reverse, 5Ј-GAAGTCAGCTGTAGAG-3Ј, which amplify the Sf1 DNA binding region 5 identified by ChIP (10) as the major in vivo Sf1 binding region in the developing male gonad. Sf1 binding to the endogenous Cyp11a1 promoter was detected using Cyp11a1 forward, 5Ј-CACTGAGGTTAGAGGCCTGG-3Ј and Cyp11a1 reverse, 5Ј-GGGAAAGTCCTTTAGCCAGC-3Ј. Endogenous Gapdh promoter amplification was used as a control of the specificity of Sf1 binding using primer Gapdh forward, 5Ј-TACTAGCGGTTTTACGGGCG-3Ј and Gapdh reverse 5Ј-TCGAACAGGAGGAGCAGAGAGCGA-3Ј. PCR amplification was carried out on a regular thermal cycler (Bio-Rad) using the following protocol: denaturation at 95 C for 30 sec; annealing at 55 C (set5) or 60 C (Gapdh) or 62 C (Cyp11a1) for 30 sec, and elongation at 72 C for 30 sec for 30 cycles. Densitometric analyses were performed using Quantity One software (Bio-Rad Laboratories).
Results
In NT2/D1 cells, ␤-catenin inhibits gene expression of SOX9 and AMH but not SRY and SF1
In male gonads and in the human testicular embryonic carcinoma cell line NT2/D1, SF1 and SRY cooperatively up-regulate SOX9 transcription, which is subsequently maintained through SF1/SOX9 cooperative interaction (10, 26) . To investigate how ␤-catenin reduces SOX9 expression to prevent male gonadal development, we first measured the expression of genes encoding regulators of SOX9 transcription in NT2/D1 cells. The canonical Wnt pathway can be activated with the broad glycogen synthase kinase-3␤ (GSK3) inhibitor lithium chloride (LiCl), or the specific GSK3␤ inhibitor BIO (27, 28) . In the absence of a Wnt signal, GSK3␤ phosphorylates ␤-catenin, which leads to its degradation; LiCl and BIO block GSK3 kinase activity, thereby increasing the level of nonphosphorylated (active) ␤-catenin levels in the cell. To verify the effect of LiCl on ␤-catenin stabilization in NT2/D1 cells, we analyzed the subcellular localization of the nonphosphorylated form of ␤-catenin by immunofluorescence (Fig. 1A) . The nonphosphorylated ␤-catenin protein was readily detected in the nucleus of nontreated cells, but its nuclear levels were markedly increased after treatment with LiCl (Fig. 1A) . In support, Western blot analysis revealed that the level of nonphosphorylated ␤-catenin in whole-cell extracts detected with an ␣ABC antibody was increased after LiCl treatment (Fig. 1B) , indicating that LiCl activates canonical Wnt signaling in NT2/D1 cells. Cells were treated with LiCl for 2 h and the levels of SRY, SF1, and SOX9 mRNA were measured by quantitative real-time RT-PCR. In LiCl-treated cells, mRNA levels of SOX9 were reduced by more than 50%, whereas SRY and SF1 mRNA levels were unchanged (Fig. 1C) . The simplest interpretation for these in vitro results is that the Wnt/␤-catenin pathway disrupts male gonadal development at the level of SOX9 transcription.
In cultured XY gonads, activation of the Wnt/␤-catenin pathway results in reduced protein levels of Sox9 and Amh but not Sry and Sf1
To investigate the inhibition of Sox9 expression by Wnt/␤-catenin in the context of mouse gonadal development, we treated cultured embryonic XY gonads with agonists of the Wnt/␤-catenin pathway. We have previously characterized the hanging-drop method of gonad culture to investigate mechanisms of gene transcription in gonadal development (29, 30). In XY gonads treated with LiCl or BIO, we first examined the subcellular localization of the nonphosphorylated form of ␤-catenin by immunohistochemistry ( Fig. 2 ) to assess whether canonical Wnt signaling was activated. Although the levels and the subcellular localization of ␤-catenin were unaltered by LiCl treatment, BIO treatment induced the expected stabilization of active ␤-catenin within the nucleus. Using these models of activation of Wnt signaling, we examined the levels of immunofluorescence staining intensity of the Sertoli cell markers, Sox9 and Amh (Fig. 3 ). Protein levels of both Sox9 and Amh appeared to be reduced by LiCl treatment (Fig. 3A) and by BIO treatment (Fig. 3B) . Next, we examined immunofluorescence staining intensity of Sf1 and Sry after LiCl or BIO treatment. Sf1 levels were unchanged (Fig. 4 , A and 4B). More specifically, using Wilms tumor 1 (Wt1) antibody as a marker of only Sertoli cells, we demonstrate that Sf1 levels remain stable in Sertoli cells as well as in Leydig cells. In addition, Wt1 immunostaining did not show any difference in the number of Sertoli cells between untreated and treated gonads.
Sry protein levels were unchanged after 12 h of treatment with either LiCl or BIO ( Fig. 4D and Supplemental Fig. 1 , left panels, published on The Endocrine Society's Journals Online web site at http://endo.endojournals.org). After 72 h in culture, Sry immunostaining intensity is markedly reduced in untreated gonads (Fig. 4D, right  panel) . This is likely due to the action of Sox9-repressing Sry expression as has been observed in vivo (8, 31) . Consistent with this, LiCl-and BIO-treated gonads expressed Sry at 72 h, which suggests that, in the absence of Sox9, Sry was no longer repressed. These ex vivo results supported by the in vitro data indicate that stabilization of ␤-catenin reduces the protein levels of Sox9 and Amh without reducing the levels of two key Sox9 transcriptional activators, Sf1 and Sry.
FIG. 1.
In NT2 cells, ␤-catenin inhibits gene expression of SOX9 and AMH without affecting SRY and SF1. A, Immunocytochemistry of NT2/D1 cells treated with or without LiCl (20 mM) for 2 h using an antibody targeted at nonphosphorylated ␣ABC. The levels of active ␤-catenin observed in the nucleus of untreated cells are strongly increased in the presence of LiCl. DAPI, 4Ј6-Diamidino-2-phenylindole, nuclear stain. Scale bars, 80 m. B, Active ␤-catenin protein levels are increased after LiCl treatment as shown in a Western blot of NT2/D1 cells using whole-cell extract. ␤-Tubulin was used as a loading control. Gels shown are representative of three independent experiments. Quantification of the level of ␣ABC, total ␤-catenin (␤cat), and ␤-tubulin was performed using Quantity One software (Bio-Rad Laboratories). Quantification was performed on three independent experiments, and error bars indicate SEM from samples from three independent experiments. *, P Ͻ 0.05 (unpaired Student's t test). C, NT2/D1 cells were treated with or without LiCl (20 mM) for 2 h. mRNA expression was measured using quantitative real-time RT-PCR. LiCl specifically represses SOX9 expression, whereas SF1 and SRY expression is not altered. Representative of three independent experiments each performed in triplicate. Bars show mean Ϯ SE. *, P Ͻ 0.05 (unpaired Student's t test).
FIG. 2.
Activated ␤-catenin protein levels reflect the action of Wnt agonists in XY gonads. Mouse embryonic XY gonads at 11.5 dpc were cultured in either control media, in media containing 20 mM LiCl, or in media containing 5 M BIO for 12 h. The culture medium was changed after 12 h, and the gonads were cultured until 3 d. Fixed gonads were processed for immunohistochemistry using the ␣ABC antibody detecting the active nonphosphorylated form of ␤-catenin. In control gonads (Ctrl), most of the active ␤-catenin is detected in the cytoplasm and membrane as it is in LiCl-treated gonads. In BIO-treated gonads, the active ␤-catenin is detected in the nucleus and cytoplasm of the cells. The difference in ␤-catenin subcellular localization between LiCland BIO-treated gonads may be explained by the difference in bioavailability of the two molecules. DAPI, 4Ј6-Diamidino-2-phenylindole, nuclear stain. Scale bars, 80 m.
Inhibition of Sox9 expression via repression of SF1 activity on the Tesco enhancer
Sox9 is transcriptionally regulated in vivo by Sry, Sox9, and Sf1 through their direct DNA binding to the testisspecific enhancer of Sox9 (Tesco) (10) . To investigate whether the Wnt pathway activation reduces Sox9 transcription via Tesco, we used cultures of transgenic gonads expressing lacZ (␤-galactosidase) under the control of Tesco (10). The 11.5 dpc gonads were harvested and cultured for 3 d in the presence of LiCl for the first 12 h and were stained for ␤-galactosidase activity to visualize enhancer activity (Fig. 5A) . Tesco-lacZ XY gonads cultured in control media expressed ␤-galactosidase, whereas littermate XX gonads showed no ␤-galactosidase activity, as expected (Fig. 5A) . (Fig. 5B) . Neither Sry nor Sox9 alone activated the Tesco enhancer, whereas Sf1 alone activated the enhancer by 10-fold (Fig. 5B, white  bars) . Synergistic activation by Sf1 and Sox9 (80-fold) or by Sf1 and Sry (20-fold) was observed, corroborating previous observations (10, 26) . Treatment of the cells with LiCl (Fig. 5B, gray bars) or BIO (Fig. 5B, black bars) reduced the activation of Tesco by Sf1 alone (3.3-fold and 3.9-fold, respectively). Synergistic activation of Tesco by either Sf1/Sox9 or Sf1/Sry was also reduced after LiCl treatment (5-fold and 3.5-fold, respectively) or BIO (5.8-fold and 5.3-fold, respectively). These data suggest that the Wnt canonical pathway inhibits Sox9 expression at the transcriptional level by reducing the ability of Sf1 to activate the Tesco enhancer.
Wnt/␤-catenin signaling inhibits Sf1 occupancy at the Tesco enhancer
Because Sf1 is also expressed in Leydig cells, activation of the Wnt signaling pathway in the whole gonad may affect Leydig cell function. ␤-Catenin is a known transcription cofactor and binding partner of Sf1, enhancing transcriptional activity on a number of Sf1 target genes in steroidogenesis (15, 16, (32) (33) (34) . For example, the human CYP11A1 promoter contains one proximal Sf1 DNA binding site (21) , and synergistic transcriptional activation by Sf1 and ␤-catenin has been reported on several P450 promoters (15, 16) . To validate that stimulation of the Wnt canonical pathway by LiCl increases CYP11A1 promoter response, plasmids encoding the proximal promoter of CYP11A1 together with Sf1 were cotransfected into NT2/D1 and HEK293T cells. An increase in the activity of the promoter was observed upon Sf1 transfection in HEK293T cells (Fig. 6A, white bars) , in accordance with previous data (21) . Treatment of the cells with LiCl stimulated the basal CYP11A1 activity indicating that activation of the canonical Wnt signaling increased the transcriptional response of the promoter (Fig. 6A, gray bars) . In NT2/D1 cells, Sf1 did not activate the promoter significantly, which has been observed in some cell lines (35, 36) ; however, in the presence of LiCl, the CYP11A1 promoter activity was significantly increased (Supplemental Fig. 2 ). In summary, activation of the Wnt signaling pathway by LiCl does not inhibit Sf1-mediated CYP11A1 transcriptional activation.
To investigate the effect of activated Wnt signaling in developing mouse gonads, we analyzed the expression of Cyp11a1 by whole-mount in situ hybridization. Consistent with previous reports in XY embryos, Cyp11a1 expression was present in both the gonad and adrenal tissue of the XY explant (21) . LiCl treatment appeared to slightly decrease Cyp11a1 expression (Fig. 6B) ; however, when assayed using quantitative realtime RT-PCR, Cyp11a1 expression in Leydig cells was unchanged, whereas Sox9 expression in Sertoli cells was significantly reduced (Fig. 6C) . These results, together with our in vitro observations, indicate that under conditions in which activation of the Wnt signaling pathway represses SF1-mediated Sox9 transcription in Sertoli cells, it has no effect upon the steroidogenic target gene of Sf1, Cyp11a1, in Leydig cells.
Because the levels of Sf1 mRNA and protein were unaffected by LiCl treatment in both NT2/D1 cells and ex vivo gonad culture, we investigated whether LiCl treatment could affect occupancy by Sf1 on the Sox9 enhancer in Sertoli cells. Because Sf1 is expressed in both Sertoli and Leydig cells, we also investigated whether LiCl treatment had an effect on Sf1 occupancy on the Cyp11a1 promoter (Fig. 7) . Chromatin was immunoprecipitated using an Sf1 antibody, and Sf1 binding on the Tesco enhancer and the Cyp11a1 promoter was assayed by semiquantitative PCR. Sf1 binding on the Tesco enhancer appeared to be male specific because Sf1 binding to the Tesco enhancer in XX gonads was not detected (compare Fig. 7, A and B, with Fig. 7, C and D) . Although it is known that the micro-ChIP technique produces higher background than the classic ChIP technique (25), we could clearly detect Sf1 binding to the Tesco enhancer in XY gonads (Fig. 7, A and B) . Sf1 occupancy on the Tesco enhancer was reduced by LiCl treatment (Fig. 7B Tesco, compare white and gray bars), whereas Sf1 occupancy on the Cyp11a1 promoter remained unchanged (Fig. 7B, Cyp11a1, compare white and gray bars) . In addition, Cyp11a1 promoter occupancy by Sf1 is male specific because Sf1 binding to the promoter was not detected in XX gonads (Fig. 7D, Cyp11a1) , which reflects the fact that Cyp11a1 is not normally expressed in XX gonads at this stage. Altogether our data suggest that the activation of the Wnt pathway inhibits Sox9 transcription by reducing Sf1 occupancy on the Sox9 enhancer Tesco. To investigate whether LiCl treatment also affects Tesco occupancy by ␤-catenin, we performed ChIP with a ␤-catenin antibody on NT2/D1 cells transfected with Sf1 (Supplemental Fig. 3 ). Sf1 binding on Tesco was strongly reduced by LiCl treatment in NT2/D1 cells as in XY gonads. Conversely, ␤-catenin occupancy on Tesco was strongly increased by treatment with LiCl, suggesting that the activation of Wnt signaling leads to increased level of ␤-catenin protein at the enhancer.
Activation of Wnt/␤-catenin signaling induces sex reversal of Sertoli cells
Because repression of Sox9 transcription can lead to a sex reversal phenotype, we examined whether the inhibition of Sox9 expression by the Wnt/␤-catenin pathway could produce a change in sexual phenotype in XY gonads when the Wnt canonical pathway was ectopically activated. Explanted gonads at 11.5 dpc were cultured for 3 d in the presence or absence of LiCl, as before. Several somatic markers of ovarian development were analyzed by whole-mount in situ hybridization. Bone morphogenic protein 2 (Bmp2) and R-spondin 1 (Rspo1) are reportedly expressed specifically in somatic cells in female gonads after 11.5 dpc (37-39). After 3 d in culture, Bmp2 and Rspo1 mRNA were detected in XX gonads and were absent from XY gonads (Fig. 8) . Treatment of XY gonads with LiCl induced the ectopic expression of both Bmp2 and Rspo1, indicative of somatic cell male-to-female sex reversal. Treatment of XX gonads with LiCl had no effect on Bmp2 or Rspo1 expression. These data indicate that ectopic Wnt signaling activation in XY gonads induces somatic sex reversal.
It should be noted, however, that Rspo1 up-regulation by active Wnt signaling was not observed previously in an in vivo model of ␤-catenin activation, and Rspo1 was actually repressed (17) . It is possible that the constant stimulation of Wnt signal in vivo triggers a negative feedback loop to down-regulate Wnt activators that were initially up-regulated, such as Rspo1 (40 -42) .The germ cell phenotype was also analyzed in the cultured gonads; however, 
because gonads in culture grow at a slower rate than in vivo (29), they do not reach the critical 14.5 dpc stage at which meiosis is observed in vivo. Consequently, we did not observe any evidence of germ cell meiosis in the untreated cultured XX gonads (Supplemental Fig. 4 ).
Discussion
Wnt/␤-catenin signaling is required for ovarian development and is also involved in repressing testicular development during embryogenesis (43, 44) . Here we shed light on the mechanism by showing that the repressive effect of ␤-catenin is to target Sf1 function. Our data suggest that the ␤-catenin-repressive effect is context dependent, targeting specifically the testis enhancer of Sox9, Tesco, while leaving steroidogenic Sf1 target promoters unaffected. The decisive effect of the Wnt/␤-catenin action that occurs in the ovary is therefore to repress Sox9 expression, allowing female development to proceed. Our results are consistent with, and provide a molecular explanation for, reports in mouse models (43, 44 ) that activation of the Wnt/␤-catenin pathway can lead to somatic cell reprogramming from male to female.
Wnt/␤-catenin represses Sox9 expression via Sf1
Because both Rspo1 and Wingless-related mouse mammary tumor virus integration site 4 (Wnt4) are expressed in the developing ovary and can signal through the Wnt canonical pathway, it has been proposed that ␤-catenin mediates this inhibitory signal and represses Sox9 expression. However, the mechanism by which the Wnt/␤-catenin pathway inhibits Sox9 expression was not known (17, 22, 43, 44) . Using NT2/D1 cells as a model of early sex determination (23, 26) , we demonstrated that the Wnt canonical pathway specifically inhibits SOX9 transcription, whereas the levels of SRY and SF1 remain intact. We cannot, however, exclude the possibility that Wnt signaling may also affect the stability of SRY, SF1, and SOX9 mRNAs. Nevertheless, our data were confirmed at the level of protein expression in XY gonad cultures treated with agonists of the Wnt canonical pathway showing a loss of Sox9 protein and the product of its target gene Amh. Consequent to the loss of Sox9 and Amh, ex vivo we observed the expression of female somatic markers. These observations corroborate in vivo findings that activation of the Wnt canonical pathway leads to male-to-female sex reversal (17) . We show that Sox9 inhibition occurs at the transcriptional level of the Sox9 gene via inhibition of Sf1-mediated transactivation of the testis-specific enhancer of Sox9, Tesco. Although we have shown that ␤-catenin directly affects Sf1 protein function, it is also possible that ␤-catenin represses Sf1 transcription at later stages of development. Indeed, Sf1 expression is normally down-regulated at 14.5 dpc in the developing ovary. We cannot exclude the possibility that ␤-catenin may also affect the function of Sry and Sox9 and vice versa through protein-protein interaction (14, 22, 45) .
Several additional transcriptional or posttranslational mechanisms involving ␤-catenin can be proposed that could result in a loss of Sox9 expression. ␤-catenin might: 1) act directly through recruiting repressors on Tesco; 2) participate in protein-protein interactions with the known activators of Tesco such as Sf1, Sry, and Sox9; or 3) regulate the transcription of Sry, Sf1, or Sox9. Our data show that ␤-catenin binding to Tesco is increased in NT2/D1 cells when Wnt signaling is activated, which suggests that ␤-catenin could be present on Tesco when the enhancer is inactive, i.e. in the ovary. ␤-Catenin may be part of a repressor complex on Tesco recruiting other Wnt repressors   FIG. 7 . Wnt/␤-catenin signaling inhibits Sf1 function on specific promoters/enhancers by inhibiting Sf1 promoter occupancy. A, ChIP of explanted XY gonad treated with or without LiCl. Mouse embryonic XY gonads at 11.5 dpc were cultured in either control media or in media containing 20 mM LiCl for 12 h. The culture medium was changed after 12 h, and the gonads were cultured until 3 d. Sonicated chromatin was immunoprecipitated with an Sf1 antibody, and promoter occupancy was assayed using specific primers for Sf1 binding sites in the Tesco enhancer or the Cyp11a1 promoter. GAPDH promoter served as a negative internal control. A representative picture of agarose gel electrophoresis of PCR products of three independent experiments is shown. B, Quantification of the gels shown in A using Quantity One software (Bio-Rad Laboratories). Quantification was performed on three independent experiments, and error bars indicate SEM from samples from three independent experiments. *, P Ͻ 0.05 (unpaired Student's t test). LiCl treatment strongly prevented Sf1 binding on the Tesco enhancer, whereas it did not affect Sf1 binding on the Cyp11a1 promoter. C and D, Identical experiments as in A and B except that XX gonads were used. Sf1 does not bind Tesco or Cyp11a1. Both Sox9 and Cyp11a1 genes are not expressed in XX gonads at this stage. *, P Ͻ 0.05 (unpaired Student's t test).
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␤-Catenin acts by selectively repressing Sf1 function in a target gene-and cell-specific manner
The identification of Sf1 as a target of the inhibitory function of the Wnt canonical pathway illustrates the likely importance of repressing Sf1 function in female gonadal development. The Wnt/␤-catenin pathway is selectively activated in XX gonads, probably due to early Rspo1 expression. Our results suggest that although stimulating the Wnt pathway does not affect Sf1 mRNA and protein levels, it does affect Sf1 protein activity by inducing a shift in occupancy of the Tesco enhancer. In contrast, in Leydig cells on the Cyp11a1 promoter, LiCl did not affect Sf1 occupancy on the promoter. Sf1 protein removal from Tesco correlated with a down-regulation of Sox9 protein levels. Thus, ␤-catenin could act as a specific coactivator of Sf1 on steroidogenic target genes in Leydig cells and could act as a specific inhibitor of Sf1 on Tesco in the granulosa cell of the developing ovary. Sf1 does not bind Tesco in female gonads, indicating that the active Wnt signaling pathway present in the ovary is sufficient to prevent Sf1 activation of Sox9 transcription.
Like Tesco, Amh transcription is also activated by the synergistic action of Sox9 and Sf1 (14) , and thus, the inhibition of Amh transcription by the Wnt/␤-catenin pathway we observed could occur either by inhibition of Sox9 transcription via the Tesco enhancer and/or removal of Sf1 from the Amh promoter, although the latter was not tested. The context-specific activation or repression of target genes by the Wnt signaling pathway may be dictated by the structure the DNA itself. The Tesco enhancer contains several Sox/Tcf transcription factor binding sites that may be recognized by ␤-catenin cofactors Tcf or Sox9/Sry. In contrast, these sites are not present in steroidogenic target promoters, such as Cyp11a1, cytochrome P450 steroid 17␣-hydroxylase/17,20 lyase (Cyp17), StAR, or 3␤-HSD that are not repressed by ␤-catenin.
Building pathways
Activation of the Wnt/␤-catenin pathway in gonad culture induced the expression of several female-specific genes in XY gonads, notably Rspo1. This observation suggests that Rspo1 is directly regulated by the Wnt signaling pathway or that the absence of Sox9 (triggered by the activation of Wnt signaling) is sufficient to up-regulate Rspo1. In vivo, activation of the Wnt signaling pathway does not immediately lead to an up-regulation of femalespecific genes (17) . Furthermore, up-regulation of femalespecific genes correlates intimately with the absence of Sox9 rather than fully activated Wnt signaling. This suggests that Sox9 could be directly involved in the repression of Rspo1 expression, which would explain our observation that Rspo1 is expressed in XY gonads treated with LiCl, which do not express Sox9.
The antagonism between the Wnt/␤-catenin pathway and Sox9 is clearly one of the molecular events driving cell fate between male and female gonads. Strong evidence suggests that Rspo1 is activating the Wnt/␤-catenin pathway in the female because the ablation of Rspo1 in female mice inactivates the Wnt/␤-catenin pathway (43) . Because Rspo1 alone does not activate the Wnt/␤-catenin pathway (47) and requires a Wnt ligand, it is likely that a Wnt protein acts in concert with Rspo1 during ovarian development. The obvious candidate for this cooperative action is Wnt4; however, ovaries of Wnt4 knockout mice still display active ␤-catenin signaling (43), which indicates that in the absence of Wnt4, Rspo1 still activates the Wnt/ ␤-catenin pathway. This suggests that a Wnt ligand other than Wnt4 cooperates with Rspo1 in the specific activation of the Wnt/␤-catenin in the ovary.
